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In his 1999 Schattuck lecture to the Massachusetts Med-
ical Society, Francis Collins provided an exciting vision of
the development of genetically based, individualised
preventive medicine by 2010.1 According to that vision,
within a decade or two it should be possible to sequence
anyone’s entire genome for a laboratory cost of less than
$1000. This would allow clinicians to provide persona-
lised advice on environmental risk and to adapt preven-
tion and treatment to an individual’s genotype. Four
years after that lecture, however, the vision of genomic
medicine is not likely to materialise anytime soon.
Coronary artery disease (CAD) and myocardial infarc-
tion (MI) are complex diseases that result from a life-long
interplay between genetic and environmental factors. To
assess an individual’s risk, clinicians currently use score
matrices based on traditional clinical and biochemical
risk factors, such as the US Framingham score2 and the
European SCORE.3 Genotypic information of interest in-
cludes common gene variants or polymorphisms (¼ gene
variants with a prevalence P1% of the rare allele in the
population) ranging from single nucleotide substitutions
(single nucleotide polymorphisms or SNPs) to insertions
or deletions in the DNA sequence, a variable number of
repeats of two or more nucleotides (VNTRs), and haplo-
types. The latter incorporate the pattern of allelic vari-
ation obtained by looking at more than one locus of
genetic variation in the DNA sequence of a gene (or the
entire chromosome) of a given individual.* Correspondence to: Tel.: +41-213140076; fax: +41-213140013.
E-mail addresses: giuseppe.vassalli@chuv.hospvd.ch (G.Vassalli);
Bernhard.Winkelmann@med.uni-heidelberg.de (B.R. Winkelmann).
 doi:10.1016/j.ehj.2003.11.014.
0195-668X/$ - see front matter c 2004 The European Society of Ca
doi:10.1016/j.ehj.2004.01.019Although many candidate genes that code for proteins
known or suspected to be involved in the pathophysiol-
ogy of atherosclerosis have been studied, early reports of
positive associations between genotype and phenotype
(generally observed in small studies) were mostly not
replicated in larger cohorts. Although there can be valid
reasons for non-replication, including multiple causative
genes and disease mechanisms, gene–environment in-
teractions, and population heterogeneity, conflicting
reports are common and perplexing, casting doubts on
this type of studies. Moreover, only genetic variants that
impart a relative risk of two or more (which is compa-
rable to that of cigarette smoking in middle-aged men)
are likely to be useful in risk algorithms. It should be
emphasised, however, that minor risk predictors in the
overall population may still impart high risk in specific
subsets, for example, due to the interaction of a gene
with other genes and the environment (e.g., cigarette
smoking).4
Myocardial infarction is the most ominous complica-
tion of CAD. Although established risk factors of CAD
predict MI as well, not all patients afflicted with CAD will
suffer from MI, suggesting that additional factors that
promote progression from a stable to an unstable ath-
erosclerotic plaque with plaque rupture and thrombosis
are involved. Most genetic association studies of CAD and
MI have focused on a single gene, thus ignoring their
multifactorial pathophysiology by excluding the remain-
der of the genome, as well as environmental factors.
However, recent advances in high-throughput genomic
technology made it possible to study multiple gene
polymorphisms. The GeneQuest study analysed 72 SNPs
within 62 genes in 352 cases with familial premature MI
and in 418 controls in a population of white Americans,
identifying a potential association with three variants of
the thrombospondin gene family.5 Another 112 poly-
morphisms in 71 candidate genes were analysed in a
Japanese study of 2819 cases with MI and 2242 controls,
identifying a potential association with SNPs in therdiology. Published by Elsevier Ltd. All rights reserved.
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1 (PAI-1) genes.6 Finally, in this month’s Journal, Tobin
and coworkers genotyped 58 SNPs in 35 genes and esti-
mated haplotypes at 14 loci encompassing 16 genes in
549 MI patients and 505 control subjects.7 Two positive
findings for SNPs (the a-adducin 460trp variant and the
CETP )629A variant) and two for the haplotypes (in the
paraoxonase and apolipoprotein C genes) were reported.
Correction for multiple testing was not performed in this
study. While we wait for such findings to be replicated in
future studies, important methodological questions can
be addressed now.
First, despite large epidemiological studies, the true
prevalence of MI remains unknown. Recently, the Euro-
pean and American Societies of Cardiology redefined the
laboratory definition for MI, which now includes plasma
troponin levels. Although this definition will pick up
smaller MIs, clinically silent MIs are frequent in advanced
CAD and it is only the tip of the iceberg that we realise
clinically. Thus, in case-control studies of MI, we should
keep in mind that cases refer to a phenotype (i.e.,
clinically diagnosed MI) that only reflects a subset of all
MIs. Consequently, identification of appropriate controls
remains a critical issue.8 Tobin and coworkers identified
visitors without a self-reported history of CAD in the
hospitals where the cases had been recruited as an ap-
proach towards a control population. Obviously, this
approach cannot rule out silent CAD in controls.
Second, the authors argue that there have been few
reports analysing a sample size of 500 cases and 500
controls or more, and that their study has a power of 90%
to detect a 1.5-fold increase in risk of MI associated with
the angiotensin-converting enzyme insertion/deletion
gene polymorphism. But will that sample size be suffi-
cient to detect a genotypic risk associated with a SNP or
haplotype in a complex disease like MI where multiple
testing is done?
Third, high-throughput genotyping and multiple hy-
pothesis testing increase the risk that associations will be
observed just by chance. According to J. Ott,9 statistical
correction for multiple testing could be performed with
the following formula: given that a1 is the probability of
a false positive result when m tests are done, each at the
a1 level, the probability that at least one of them leads
to a false positive result is am ¼ 1 ð1 a1Þm. For in-
stance, to keep am at a level of 0.05, one must carry out
each individual test at the a1 level, which can be calcu-
lated as a1 ¼ 1 ð1 amÞð1=mÞ. To meet an overall sig-
nificance level of am ¼ 0:05, the individual significance
level a1 needs to be set at p ¼ 0:001 if 50 independent
tests are carried out, or at p ¼ 0:0005 if 100 tests are
carried out, in order to call any of them positive. None of
these significance levels is met by the data of Tobin and
coworkers, leaving us wondering whether we are dealing
with false positive results. A recent association study of
207 SNPs in 110 genes in a subset of 305 unrelated indi-
viduals with premature MI from the GeneQuest study
identified 8 genes associated with the metabolic syn-
drome (p-values ranging from 0.008 to 0.047), but simi-
larly failed to correct for multiple testing.10 The general
excuse of omitting this correction is the intention to doan exploratory hypothesis-generating study. If standards
were set too high, important candidate genes might be
missed. Without correction for multiple testing, how-
ever, any such results are to be regarded with extreme
caution before they are replicated in independent stud-
ies. Especially in the case of low allelic frequencies of
the mutant allele (i.e. <10%), minor changes in preva-
lence may lead to significant or non-significant results
(see Table 3 in Bugert et al.11). Thus, validation will re-
quire large databases of carefully defined clinical
phenotypes and accurate genotyping data, along with
long-term follow-up for key clinical endpoints in order to
assess the clinical relevance of such genetic variation.
The study by Tobin and coworkers seems to provide
more questions than answers, following the general
pattern of studies on genetic associations of common
diseases. For most polymorphisms, therapeutic implica-
tions in complex diseases are a long way off. Thus, val-
idated genetic approaches to the prevention and
treatment of common diseases are unlikely to be avail-
able by 2010. Instead, we currently are witnessing a
proliferation of pseudoscientific approaches involving
direct-to-consumer marketing of genetic tests and ge-
netic testing sites on the Internet. In the United King-
dom, for instance, a chain of health stores began to sell a
series of nine genetic tests in combination with a life-
style questionnaire, which allegedly offered “genetically
tuned” advice. Not only are these tests of little useful-
ness, if any, but they can also cause anxiety or false
reassurance.
We are entering a new era of genetic association
analyses for complex diseases. High-throughput geno-
typing makes it possible to test as many as 1 million
genetic variants in a given individual using recently de-
veloped microchips.12 Future studies need to address
evolutionary relations among haplotypes and tackle the
issue of gene–gene and gene–environment interaction in
order to bring us closer to genomic medicine. However,
these approaches will come with new challenges.
Therefore, at the moment, studies like the one reported
by Tobin et al.7 are very important and useful, as long as
we keep in mind their limitations.References
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